<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00226304</url>
  </required_header>
  <id_info>
    <org_study_id>050246</org_study_id>
    <secondary_id>05-CC-0246</secondary_id>
    <nct_id>NCT00226304</nct_id>
  </id_info>
  <brief_title>Evaluation of Brain Lesions in HIV-infected Patients for Diagnosis of Primary Central Nervous System Lymphoma</brief_title>
  <official_title>The Evaluation of Focal Contrast-Enhancing Brain Lesions in HIV-Infected Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institutes of Health Clinical Center (CC)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      This study will evaluate the usefulness of two tests in quickly distinguishing whether a
      patient with HIV infection and focal brain lesions (an injury in a specific area of the
      brain) has a rare type of cancer called primary central nervous system lymphoma (PCNSL), or a
      parasitic infection called toxoplasmic encephalitis.

      Toxoplasmic encephalitis is caused by a parasite and can be treated with antibiotics. PCNSL
      (lymphoma of the brain or spinal cord) must be definitively diagnosed with a brain biopsy
      (removal of a small piece of brain tissue), and the treatment is radiation therapy and
      chemotherapy.

      The tests under study for diagnosing PCNSL or toxoplasmic encephalitis are measurement of
      Epstein Barr virus (EBV) DNA in cerebrospinal fluid (CSF) and FDG-PET scan of the brain. EBV
      is often found in the CSF of people with PCNSL. The study also will compare the accuracy of
      two imaging techniques-TI-SPECT and FDG-PET-in distinguishing between toxoplasmosis and
      PCNSL.

      Patients 18 years of age and older who have HIV infection and at least one focal brain lesion
      without a prior history of PCNSL or toxoplasmic encephalitis may be eligible for this study.
      Each candidate is screened with a medical history, physical examination, blood and urine
      tests and MRI scans of the brain.

      Upon entering the study, all participants take medication to treat toxoplasmic encephalitis.
      They undergo lumbar puncture (spinal tap) to obtain CSF for analysis, an FDG-PET scan, and a
      201TI-SPECT scan. For the PET scan, a radioactive substance is injected into an arm, followed
      by scanning in a doughnut-shaped machine similar to a CT scanner. SPECT is similar to PET but
      uses a different radioactive tracer, and the patient lies on a table while the SPECT camera
      rotates around the patient's head. Patients whose test results indicate a low risk for
      lymphoma continue antibiotic therapy for toxoplasmosis. They have repeat MRI scans around 4,
      7, and 14 days after starting the drug to monitor the response to therapy. Antiretroviral
      therapy is initiated in patients who are not already on such a regimen.

      Patients whose test results indicate a high risk for PCNSL have a CT scan to look for
      evidence of lymphoma elsewhere in the body and are referred for consultation with a
      neurosurgeon to discuss undergoing a brain biopsy. The brain biopsy is done in the operating
      room under general anesthesia. A small cut is made in the scalp and a small opening is made
      in the skull over the area of the brain to be biopsied. A needle is placed in the opening in
      the skull and, guided by CT or MRI, moved to the abnormal area of the brain, where a small
      piece of tissue is removed for study under a microscope.

      Patients found to have toxoplasmosis are discharged from the hospital to the care of their
      primary care physician after they are getting better and are tolerating all their
      medications. They return to NIH for follow-up visits about 4 weeks, and 6 months after
      discharge.

      Patients found to have lymphoma are referred to the National Cancer Institute for screening
      for enrollment in a treatment protocol. Patients who are not eligible for a treatment
      protocol are referred back to their primary care physician or for another NIH treatment
      protocol, if one is available. Patients with lymphoma are seen at the NIAID outpatient clinic
      for follow-up visits and laboratory examinations every 3 months for 2 years.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Epstein Barr Virus (EBV)-associated primary central nervous system lymphoma (PCNSL) remains a
      major problem among AIDS patients. The clinical presentation is often clinically
      indistinguishable from toxoplasmic encephalitis. The method of choice for establishing the
      definitive diagnosis is brain biopsy. This procedure can be associated with a significant
      morbidity and mortality, and therefore less invasive means of diagnosing cerebral mass
      lesions have been studied.

      Currently, an accepted standard of care for HIV-infected patients that present with signs and
      symptoms of focal brain lesions is to empirically treat for toxoplasmic encephalitis. Brain
      biopsy is often deferred until there is demonstration of lack of clinical response or
      progression on empiric therapy. As a result, treatment initiation is frequently delayed.
      During this time it is not unusual for further clinical deterioration to occur before
      appropriate therapies can be initiated. Frequently, the alternative approaches then become a
      question of appropriate palliation rather than curative intent therapy.

      Less invasive diagnostic tests to assist in the diagnosis have been investigated. Based on
      the finding that essentially 100% of HIV-related PCNSL are EBV-associated, the detection of
      EBV DNA by PCR amplification in the cerebrospinal fluid (CSF) has demonstrated clinical
      usefulness in the diagnosis, as has the use of neuroradiologic imaging to detect the
      malignancy. Prior studies have demonstrated that the use of a combination of neuroradiologic,
      immunologic, and clinical variables in the workup of focal brain lesions in HIV-infected
      patients to be quite accurate in identifying patients in need of brain biopsy, but a
      diagnostic algorithm that incorporates the combination of the most sensitive and specific
      tests in a timely manner has not yet been explored.

      This study seeks to evaluate an algorithm for the workup of HIV infected patients with focal
      brain lesions so as to expedite the diagnosis and subsequent treatment of PCNSL. The goals of
      the study are to 1) determine the specificity, sensitivity, and positive predictive value of
      a diagnostic algorithm that entails the use of the combination of EBV detection in the CSF
      and FDG-PET scanning to diagnose PCNSL; 2) evaluate the time to response to anti-toxoplasmic
      encephalitis therapy, and 3) evaluate the sensitivities and specificities of FDG-PET and
      (201)Tl-SPECT scanning in identifying PCNSL. Up to one hundred HIV-infected patients with
      history of at least one focal brain lesion will be screened for enrollment. All patients will
      be treated empirically for toxoplasmic encephalitis until an alternative diagnosis is
      confirmed. All enrolled patients will be treated concurrently with antiretroviral therapy.
      Patients identified to have PCNSL will be referred to the NCI Treatment of PCNSL Protocol for
      further treatment if the study is open for enrollment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 20, 2005</start_date>
  <completion_date>April 15, 2009</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <enrollment>120</enrollment>
  <condition>HIV Infections</condition>
  <condition>Lymphoma, AIDS-Related</condition>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:

        Adult (18 years old or older) HIV-infected patient

        HIV infected by OraQuick rapid test using saliva, venipuncture whole blood, or fingerstick
        whole blood; or by reactive ELISA and Western Blot as determined by an outside
        CLIA-approved laboratory facility or by NIH Clinical Pathology Laboratory or SAIC-Frederick
        Inc Monitoring Laboratory. HIV infection as determined by an outside CLIA-approved
        laboratory facility will be verified by a standard HIV-1 ELISA with Western Blot
        confirmation prior to brain biopsy.

        Evidence of contrast-enhancing focal brain lesion(s) as seen on MRI or CT

        Willingness to give informed consent and provided by Durable Power of Attorney. In the
        event that no Durable Power of Attorney has been designated and the patient is unable to do
        so, the NIH Ethics Committee will be consulted. All patients must designate a Durable Power
        of Attorney in order to participate in the study.

        Willingness to undergo the procedures involved in the diagnostic evaluation: lumbar
        puncture, FDG-PET scan, 201Tl-SPECT scan, and brain biopsy.

        Permit the storage of blood, CSF, and tissue samples for future research use

        Willingness to undergo HLA testing

        EXCLUSION CRITERIA:

        Previous PCNSL

        History of prior malignancy other than PCNSL unless in remission for 1 year or longer;
        non-melanoma skin cancer and Kaposi's sarcoma excepted

        History of previous diagnosis of toxoplasmic encephalitis or other CNS infection causing
        focal contrast-enhancing brain lesions

        Pregnancy or currently breast feeding

        Have any other condition that the research team considers a contraindication to
        participating in the study, e.g. severe cardiac, renal, or pulmonary dysfunction.

        Weight greater than 400 lb for PET and 500 lb for SPECT (limit of the gantry).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Cot√© TR, Manns A, Hardy CR, Yellin FJ, Hartge P. Epidemiology of brain lymphoma among people with or without acquired immunodeficiency syndrome. AIDS/Cancer Study Group. J Natl Cancer Inst. 1996 May 15;88(10):675-9.</citation>
    <PMID>8627644</PMID>
  </reference>
  <reference>
    <citation>Basso U, Brandes AA. Diagnostic advances and new trends for the treatment of primary central nervous system lymphoma. Eur J Cancer. 2002 Jul;38(10):1298-312. Review.</citation>
    <PMID>12091059</PMID>
  </reference>
  <reference>
    <citation>MacMahon EM, Glass JD, Hayward SD, Mann RB, Becker PS, Charache P, McArthur JC, Ambinder RF. Epstein-Barr virus in AIDS-related primary central nervous system lymphoma. Lancet. 1991 Oct 19;338(8773):969-73.</citation>
    <PMID>1681341</PMID>
  </reference>
  <verification_date>April 15, 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 23, 2005</study_first_submitted>
  <study_first_submitted_qc>September 23, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 26, 2005</study_first_posted>
  <last_update_submitted>June 30, 2017</last_update_submitted>
  <last_update_submitted_qc>June 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2017</last_update_posted>
  <keyword>Focal Brain Lesions</keyword>
  <keyword>AIDS</keyword>
  <keyword>Lymphoma</keyword>
  <keyword>EBV</keyword>
  <keyword>FDG-PET</keyword>
  <keyword>HIV Infection</keyword>
  <keyword>Brain Lesion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Lymphoma, AIDS-Related</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

